About Specific Technologies
Specific Technologies is a company based in San Francisco (United States) founded in 2009 by Paul Rhodes and Ray Martino was acquired by BioMerieux in April 2022. Specific Technologies has raised $30 million across 2 funding rounds from investors including BioMerieux and Telegraph Hill Partners. Specific Technologies operates in a competitive market with competitors including Cepheid, Day Zero Diagnostics, SeLux Diagnostics, SpinDiag and MicrobeDx, among others.
- Headquarter San Francisco, United States
- Founders Paul Rhodes, Ray Martino
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30 M (USD)
in 2 rounds
-
Latest Funding Round
$17.5 M (USD), Series A
Feb 10, 2020
-
Investors
BioMerieux
& 1 more
-
Employee Count
Not available
-
Acquired by
BioMerieux
(Apr 12, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Specific Technologies
Unlock access to complete
Unlock access to complete
Funding Insights of Specific Technologies
Specific Technologies has successfully raised a total of $30M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $17.5 million completed in February 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Specific Technologies
Specific Technologies has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BioMerieux and Telegraph Hill Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science, medical device and healthcare companies
|
Locked | Locked | Locked | |
|
Developer of diagnostics devices for multiple health purposes
|
Locked | Locked | Locked |
Investor details for Specific Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Specific Technologies
Investment portfolio details for Specific Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Specific Technologies
Detailed financials for Specific Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Specific Technologies Comparisons
Peer comparison for Specific Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Specific Technologies
Specific Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Cepheid, Day Zero Diagnostics, SeLux Diagnostics, SpinDiag and MicrobeDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of molecular diagnostic testing solutions
|
|
| Locked | Locked | Locked |
Genome sequencing diagnostics for infectious diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of alternatives to traditional ELISA assays
|
|
| Locked | Locked | Locked |
Point-of-care systems for screening drug-resistant pathogens are developed.
|
|
| Locked | Locked | Locked |
Provider of the solutions for the detection of antibiotic susceptibility in urinary tract infections
|
Detailed competitors of Specific Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Specific Technologies
Complete news archive for Specific Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Specific Technologies
Specific Technologies was founded in 2009 and raised its 1st funding round 10 years after it was founded.
Specific Technologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Paul Rhodes is the current CEO of Specific Technologies. They have also founded this company.
Specific Technologies is a funded company, having raised a total of $30M across 2 funding rounds to date.
Specific Technologies was founded in 2009 and is based in San Francisco, United States. Operations focus on the diagnostics sector, where blood infection detection and antibiotic susceptibility testing are conducted. Two products, Reveal AST and Reveal ID, are offered, both supporting susceptibility assessments. Leadership includes co-founder and CEO Paul Rhodes, alongside founder Ray Martino. Services target healthcare applications in infection management.
Specific Technologies's top competitors include Cepheid, Day Zero Diagnostics and SeLux Diagnostics.
Specific Technologies has 2 investors. Key investors include BioMerieux, and Telegraph Hill Partners.